CN101810759A - Curbitacin-containing medicine - Google Patents
Curbitacin-containing medicine Download PDFInfo
- Publication number
- CN101810759A CN101810759A CN 201010158627 CN201010158627A CN101810759A CN 101810759 A CN101810759 A CN 101810759A CN 201010158627 CN201010158627 CN 201010158627 CN 201010158627 A CN201010158627 A CN 201010158627A CN 101810759 A CN101810759 A CN 101810759A
- Authority
- CN
- China
- Prior art keywords
- grams
- extract
- radix
- rhizoma
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a synergetic medicinal composition containing curbitacin and Chinese herb extract and an application thereof in the preparation of medicine for assisting the treatment of hepatitis.
Description
Invention field
The present invention relates to the Pharmaceutical composition formed by cucurbitacin and Chinese medicine extract, and the purposes of said composition in the medicine of preparation adjuvant treating hepatitis.
Background technology
Hepatitis has multiple sorting technique clinically, classifies as (1) nosetiology: viral hepatitis can be divided into five types is first, second, third, fourth, penta.(2) clinical classification can be divided into following a few type: 1. acute anicteric hepatitis, this is a modal type in the viral hepatitis, see with B-mode, third type, hepatitis D more, general this type of hepatitis clinical symptoms is less, and transaminase's elevated levels is lower, and Histological change is light, mortality rate is lower, but the course of disease can be delayed the long period, and " three is slow " characteristics are arranged, and morbidity is slow, recovery is slow, delay also slow (referring to the long meaning slowly); 2. acute icterohepatitis is less relatively compared with anicteric hepatitis, and the state of an illness is a self limiting often, and how good prognosis is, but minority can develop into hepatitis gravis; 3. chronic hepatitis: relevant experts in 1994 propose the name and the suggestion of chronic hepatitis again, with the cause of disease is the diagnosis name that chronic hepatitis is determined on the basis, simultaneously ordered grade scale, formulated standard by stages according to degree of hepatic fibrosis again according to the downright bad order of severity of hepatitis inflammation; 4. hepatitis gravis can be divided into acute heavy type, severe subacute and chronic heavy type again; 5. cholestatic hepatitis.
Wherein hepatitis B is caused by hepatitis B virus, serves as main a kind of infectious disease that also can cause multiple organ injury with the liver inflammatory lesion.China is the most popular country of hepatitis B, reaches more than 35% some local crowd infection rate, and be the most serious infectious disease of current harm people ' s health.According to investigations, China's hepatitis B patient is about 2,700 ten thousand, and annual New Development patient about 9,000,000.
The hepatitis B clinical manifestation is various, easily develops into chronic hepatitis and liver cirrhosis, and a few peoples finally develop into hepatocarcinoma.Hepatic fibrosis is the total pathological change of many chronic hepatopathy evolutions, and the damage of chronic, persistence is the prerequisite that hepatic fibrosis forms.Cause the factor of hepatic injury a lot,, hepatitis B, liver cirrhosis, take some drugs for a long time and can cause acute and chronic liver injury generally because of factors such as medicine, a large amount of ethanol, allergy cause acute liver damage.By reducing detrimental effect to liver function, can adjuvant treating hepatitis.
The medicine that is used for the treatment of the acute and chronic hepatic injury at present, commonly used have cucurbitacin, a diammonium glycyrrhizinate etc.These chemicalses generally have certain side effect, and cause that therapeutic effect at a specified future date is poor, problem such as Strain produces after drug resistance phenomenon, the drug withdrawal relapse rate height.
The curative effect of Chinese medicine hepatitis B is proved by a large amount of clinical trials.Chinese medicine all can be brought into play curative effect preferably at aspects such as antiviral, adjusting immunity of organisms, protection hepatocyte.But Chinese medicine preparation ubiquity onset at present is slow, needs problems such as life-time service.
Therefore, Western medicine and Chinese Medicine and Clavicular need be got up, i.e. synergism is played in Chinese medicine and western medicine combination, solves the problem that above-mentioned Western medicine and Chinese medicine exist in auxiliary treatment all kinds hepatitis separately, produces synergistic therapeutic effect simultaneously.
Summary of the invention
One object of the present invention is to provide the Pharmaceutical composition of being made up of cucurbitacin and a kind of Chinese medicine extract, and wherein the Chinese medicine extract of said composition prepares according to the method for embodiment 1 among the Chinese patent CN1056755C, and is as follows:
Herba Epimedii 10 grams, Rhizoma Polygoni Cuspidati 10 grams, Radix Paeoniae Rubra 10 grams, Herba Taraxaci 10 grams, the Radix Astragali 10 grams, Radix Et Rhizoma Rhei 5 grams, Ganoderma 10 grams, Fructus Ligustri Lucidi 8 grams, root of subprostrate sophora 5 grams, Rhizoma Smilacis Glabrae 10 grams; With the Diluted Alcohol 70-85% lixiviate of Ganoderma, Herba Epimedii, Rhizoma Smilacis Glabrae, extracting solution merges; With Herba Taraxaci, Rhizoma Polygoni Cuspidati, the Radix Astragali, root of subprostrate sophora, Fructus Ligustri Lucidi, Radix Paeoniae Rubra, Radix Et Rhizoma Rhei add decocting in water, and the water extract merges, and merge with the water extract behind the ethanol extract decompression recycling ethanol, and concentrating under reduced pressure is drying to obtain extract.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in preparation auxiliary treatment all kinds hepatitis medicament.
This Chinese medicine the water extracted immersing paste is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has strong transaminase lowering effect, i.e. function for protecting liver and reducing enzyme activity.
Edit with reference to Zhang Juntian, " modern pharmacology test method " (volume two), combined publication society of China Concord Medical Science University of Beijing Medical University, the 1397-1398 page or leaf, disclosed method in " first segment chmice acute chemical liver injury model ", set up the acute chemical liver injury model of mouse carbon tetrachloride, carry out the pharmacodynamics test of Pharmaceutical composition anti-liver injury of the present invention.
The test grouping:
1, normal control group: animal does not do any processing, and normal physiological saline is irritated stomach;
2, model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
3, pure Chinese drug-treated group: the water extracted immersing paste 0.89g/kg body weight as indicated above
4, cucurbitacin group: the 10mg/kg body weight is irritated stomach
5, compositions group: 10mg/kg body weight cucurbitacin+the water extracted immersing paste 0.89g/kg body weight mentioned above is irritated stomach.
Following table has shown the influence of each group to Mouse Liver function leading indicator GOT, GPT.
| Group | Number of animals | GOT (active unit) | GPT (active unit) |
| The normal control group | ??10 | ??26.12±18.51 | ??49.22±19.23 |
| Model control group | ??10 | ??252.16±77.82 | ??298.96±57.83 |
| Pure Chinese drug-treated group | ??10 | ??177.35±58.12 | ??239.93±56.31 |
| The cucurbitacin group | ??10 | ??110.82±39.72 | ??208.52±32.82 |
| The compositions group | ??10 | ??88.73±33.65 | ??108.27±46.81 |
This table shows that all there is significant difference (P＜0.05) in each group (pure Chinese drug-treated group, cucurbitacin group, compositions group) of treatment with model control group, and all there are significant difference (P＜0.05) in compositions group and pure Chinese drug-treated group, compositions group and cucurbitacin group.Show that there are cooperative effect in cucurbitacin and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio cucurbitacin and Chinese medicine extract mentioned above at 1: 89.
Can produce the capsule that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Talcum 5.0
Wherein compositions is made up of with weight ratio cucurbitacin and Chinese medicine extract mentioned above at 1: 89.
Claims (2)
1. Pharmaceutical composition, it is made up of with weight ratio cucurbitacin and Chinese medicine extract at 1: 89, and described Chinese medicine extract is by following method preparation:
Herba Epimedii 10 grams, Rhizoma Polygoni Cuspidati 10 grams, Radix Paeoniae Rubra 10 grams, Herba Taraxaci 10 grams, the Radix Astragali 10 grams, Radix Et Rhizoma Rhei 5 grams, Ganoderma 10 grams, Fructus Ligustri Lucidi 8 grams, root of subprostrate sophora 5 grams, Rhizoma Smilacis Glabrae 10 grams; Ganoderma, Herba Epimedii, Rhizoma Smilacis Glabrae invaded with Diluted Alcohol 70-85% carry, extracting solution merges; Herba Taraxaci, Rhizoma Polygoni Cuspidati, the Radix Astragali, root of subprostrate sophora, Fructus Ligustri Lucidi, Radix Paeoniae Rubra, Radix Et Rhizoma Rhei are added decocting in water, and the water extract merges, and merges with the water extract behind the ethanol extract decompression recycling ethanol, and concentrating under reduced pressure is drying to obtain extract.
2. the purposes of compositions as claimed in claim 1 in the medicine of preparation adjuvant treating hepatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101586271A CN101810759B (en) | 2010-04-27 | 2010-04-27 | Curbitacin-containing medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101586271A CN101810759B (en) | 2010-04-27 | 2010-04-27 | Curbitacin-containing medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101810759A true CN101810759A (en) | 2010-08-25 |
| CN101810759B CN101810759B (en) | 2011-08-31 |
Family
ID=42618219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101586271A Expired - Fee Related CN101810759B (en) | 2010-04-27 | 2010-04-27 | Curbitacin-containing medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101810759B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118576681A (en) * | 2024-08-06 | 2024-09-03 | 深圳市安美信生物医药科技有限公司 | A liver protection composition and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106690A (en) * | 1994-11-19 | 1995-08-16 | 天津市第一医院 | Medicine of curing hepatitis |
| CN1899492A (en) * | 2006-07-06 | 2007-01-24 | 张砚 | Synergistic medicinal composition for treating hepatitis |
-
2010
- 2010-04-27 CN CN2010101586271A patent/CN101810759B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106690A (en) * | 1994-11-19 | 1995-08-16 | 天津市第一医院 | Medicine of curing hepatitis |
| CN1899492A (en) * | 2006-07-06 | 2007-01-24 | 张砚 | Synergistic medicinal composition for treating hepatitis |
Non-Patent Citations (3)
| Title |
|---|
| 《中国新药杂志》 19961231 李庶心等 《防治慢性肝炎药物使用现状及研究进展》 401-406 1-2 第5卷, 第6期 2 * |
| 《中国药店》 20021231 刘宁 《肝炎用药简析》 64 1-2 , 第9期 2 * |
| 《齐鲁药事》 20051231 么焕开等 《葫芦素的研究概况》 737-739 1-2 第24卷, 第12期 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118576681A (en) * | 2024-08-06 | 2024-09-03 | 深圳市安美信生物医药科技有限公司 | A liver protection composition and preparation method thereof |
| CN118576681B (en) * | 2024-08-06 | 2024-10-22 | 深圳市安美信生物医药科技有限公司 | Liver protecting composition and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101810759B (en) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101810694B (en) | Traditional Chinese medicine and western medicine composition for adjunctive therapy of hepatitis | |
| CN100356960C (en) | Synergistic medicinal composition for treating hepatitis | |
| CN101502551B (en) | Synergistic composition containing bifendate | |
| CN100353992C (en) | Medicine for auxiliary treating hepatitis | |
| CN101810759B (en) | Curbitacin-containing medicine | |
| CN100363040C (en) | Medicinal compositions comprising biphenyldicarboxylate | |
| CN100356958C (en) | Synergistic medicinal composition for treating hepatitis | |
| CN101850003B (en) | Traditional Chinese medicine and western medicine compound for protecting liver and decreasing enzyme | |
| CN101843822B (en) | Medicinal composition containing traditional Chinese medicine extract | |
| CN100421690C (en) | Chinese-western medicine composition for treating hepatitis | |
| CN101837036B (en) | Synergetic medicinal composition | |
| CN100393337C (en) | Synergistic medicinal composition | |
| CN100421697C (en) | Synergistic medicinal composition containing diammonium glycyrrhizinate and Chinese medicine | |
| CN100363045C (en) | Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate for treating hepatitis accessorily | |
| CN100363035C (en) | Cooperative medicinal composition comprising biphenyldicarboxylate and traditional Chinese medicine extract | |
| CN100421704C (en) | Drug comprising biphenyldicarboxylate | |
| CN100353981C (en) | Medicine for auxiliary treating hepatitis | |
| CN101721597B (en) | Pharmaceutical composition containing oleanolic acid | |
| CN101797337B (en) | Medicine containing Guadisu | |
| CN101837064B (en) | Epomediol-containing medicament composition for protecting liver and decreasing enzyme | |
| CN100434096C (en) | Drug for treating hepatitis comprising biphenyldicarboxylate | |
| CN100450507C (en) | Chinese traditional medicine and western medicine composition for treating hepatitis | |
| CN100363041C (en) | Traditional Chinese medicine and western medicine cooperative compositions comprising biphenyldicarboxylate | |
| CN100353978C (en) | Synergistic medicinal composition containing tiopronin and Chinese medicine extract | |
| CN100569253C (en) | A kind of medicine of adjuvant treating hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LUO DANXIAO Free format text: FORMER OWNER: ZHANG DAYU Effective date: 20110524 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Luo Danxiao Inventor before: Zhang Dayu |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100070 BUILDING 18, AREA 8, HEADQUARTER BASE, NO. 188, SOUTH 4TH RING ROAD WEST, FENGTAI DISTRICT, BEIJING TO: 315153 XIANGMEI JIAYUAN RESIDENTIAL QUARTER, SHIQUAN ROAD, SHIQI SUBDISTRICT, YINZHOU DISTRICT, NINGBO CITY, ZHEJIANG PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHANG DAYU TO: LUO DANXIAO |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110524 Address after: 315153 Zhejiang city of Ningbo province Yinzhou District Shiqi Street Shiquan Road Xiangmei Garden Applicant after: Luo Danxiao Address before: 100070, No. 18, building eight, 188, base station, South Fourth Ring Road West, Beijing, Fengtai District Applicant before: Zhang Dayu |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG HUAKE INTELLECTUAL PROPERTY SERVICE CO., L Free format text: FORMER OWNER: LUO DANXIAO Effective date: 20121221 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 315153 NINGBO, ZHEJIANG PROVINCE TO: 226600 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121221 Address after: 226600 No. 8 Yingbin Road, Chengdong Town, Haian County, Nantong, Jiangsu Patentee after: Nantong Huake Intellectual Property Service Co.,Ltd. Address before: 315153 Zhejiang city of Ningbo province Yinzhou District Shiqi Street Shiquan Road Xiangmei Garden Patentee before: Luo Danxiao |
|
| ASS | Succession or assignment of patent right |
Owner name: HAIAN CHANGDA TECHNOLOGY TRANSFER CENTER CO., LTD. Free format text: FORMER OWNER: NANTONG HUAKE INTELLECTUAL PROPERTY SERVICE CO., LTD. Effective date: 20140514 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140514 Address after: 226600 No. 8 Yingbin Road, Haian County, Nantong, Jiangsu Patentee after: HAIAN CHANGZHOU UNIVERSITY TECHNOLOGY TRANSFER CENTER Co.,Ltd. Address before: 226600 No. 8 Yingbin Road, Chengdong Town, Haian County, Nantong, Jiangsu Patentee before: Nantong Huake Intellectual Property Service Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20221226 Address after: 413, Floor 4, Building B, Innovation Building, Linyi Hi tech Industrial Development Zone, Shandong Province, 276000 Patentee after: Linyi High tech Zone Jinlanling Labor Service Co.,Ltd. Address before: 226600 No.8 Yingbin Road, Hai'an County, Nantong City, Jiangsu Province Patentee before: HAIAN CHANGZHOU UNIVERSITY TECHNOLOGY TRANSFER CENTER Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110831 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |